Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 LAMEA Oncology Drugs Market, by Indication
1.4.2 LAMEA Oncology Drugs Market, by Drug Class Type
1.4.3 LAMEA Oncology Drugs Market, by Country
1.5 Methodology for the research
Chapter 2. Market at a Glance
2.1 Key Highlights
Chapter 3. Market Overview
3.1 Introduction
3.1.1 Overview
3.1.1.1 Market Composition and Scenario
3.2 Key Factors Impacting the Market
3.2.1 Market Drivers
3.2.2 Market Restraints
Chapter 4. Competition Analysis - Global
4.1 KBV Cardinal Matrix
4.2 Recent Industry Wide Strategic Developments
4.2.1 Partnerships, Collaborations and Agreements
4.2.2 Product Launches and Product Expansions
4.2.3 Acquisition and Mergers
4.3 Top Winning Strategies
4.3.1 Key Leading Strategies: Percentage Distribution (2019-2023)
4.3.2 Key Strategic Move: (Partnerships, Collaborations & Agreements : 2019, Mar – 2023, Nov) Leading Players
4.4 Porter’s Five Forces Analysis
Chapter 5. LAMEA Oncology Drugs Market by Indication
5.1 LAMEA Breast Cancer Market by Country
5.2 LAMEA Prostate Cancer Market by Country
5.3 LAMEA Lung Cancer Market by Country
5.4 LAMEA Stomach Cancer Market by Country
5.5 LAMEA Colorectal Cancer Market by Country
5.6 LAMEA Liver Cancer Market by Country
5.7 LAMEA Esophagus Cancer Market by Country
5.8 LAMEA Cervical Cancer Market by Country
5.9 LAMEA Kidney Cancer Market by Country
5.10. LAMEA Bladder Cancer Market by Country
5.11 LAMEA Other Cancer Market by Country
Chapter 6. LAMEA Oncology Drugs Market by Drug Class Type
6.1 LAMEA Targeted Therapy Market by Country
6.2 LAMEA Immunotherapy (Biologic Therapy) Market by Country
6.3 LAMEA Chemotherapy Market by Country
6.4 LAMEA Hormonal Therapy Market by Country
Chapter 7. LAMEA Oncology Drugs Market by Country
7.1 Brazil Oncology Drugs Market
7.1.1 Brazil Oncology Drugs Market by Indication
7.1.2 Brazil Oncology Drugs Market by Drug Class Type
7.2 Argentina Oncology Drugs Market
7.2.1 Argentina Oncology Drugs Market by Indication
7.2.2 Argentina Oncology Drugs Market by Drug Class Type
7.3 UAE Oncology Drugs Market
7.3.1 UAE Oncology Drugs Market by Indication
7.3.2 UAE Oncology Drugs Market by Drug Class Type
7.4 Saudi Arabia Oncology Drugs Market
7.4.1 Saudi Arabia Oncology Drugs Market by Indication
7.4.2 Saudi Arabia Oncology Drugs Market by Drug Class Type
7.5 South Africa Oncology Drugs Market
7.5.1 South Africa Oncology Drugs Market by Indication
7.5.2 South Africa Oncology Drugs Market by Drug Class Type
7.6 Nigeria Oncology Drugs Market
7.6.1 Nigeria Oncology Drugs Market by Indication
7.6.2 Nigeria Oncology Drugs Market by Drug Class Type
7.7 Rest of LAMEA Oncology Drugs Market
7.7.1 Rest of LAMEA Oncology Drugs Market by Indication
7.7.2 Rest of LAMEA Oncology Drugs Market by Drug Class Type
Chapter 8. Company Profiles
8.1 AbbVie, Inc.
8.1.1 Company Overview
8.1.2 Financial Analysis
8.1.3 Regional Analysis
8.1.4 Research & Development Expense
8.1.5 Recent strategies and developments:
8.1.5.1 Partnerships, Collaborations, and Agreements:
8.1.5.2 Acquisition and Mergers:
8.1.6 SWOT Analysis
8.2 Amgen, Inc.
8.2.1 Company Overview
8.2.2 Financial Analysis
8.2.3 Regional Analysis
8.2.4 Research & Development Expenses
8.2.5 Recent strategies and developments:
8.2.5.1 Acquisition and Mergers:
8.2.6 SWOT Analysis
8.3 Astellas Pharma, Inc.
8.3.1 Company Overview
8.3.2 Financial Analysis
8.3.3 Regional Analysis
8.3.4 Research & Development Expense
8.3.5 Recent strategies and developments:
8.3.5.1 Partnerships, Collaborations, and Agreements:
8.3.5.2 Acquisition and Mergers:
8.3.6 SWOT Analysis
8.4 AstraZeneca PLC
8.4.1 Company Overview
8.4.2 Financial Analysis
8.4.3 Regional Analysis
8.4.4 Research & Development Expenses
8.4.5 Recent strategies and developments:
8.4.5.1 Partnerships, Collaborations, and Agreements:
8.4.5.2 Product Launches and Product Expansions:
8.4.6 SWOT Analysis
8.5 Bristol Myers Squibb Company
8.5.1 Company Overview
8.5.2 Financial Analysis
8.5.3 Regional Analysis
8.5.4 Research & Development Expenses
8.5.5 Recent strategies and developments:
8.5.5.1 Partnerships, Collaborations, and Agreements:
8.5.5.2 Product Launches and Product Expansions:
8.5.5.3 Acquisition and Mergers:
8.5.6 SWOT Analysis
8.6 F. Hoffmann-La Roche Ltd.
8.6.1 Company Overview
8.6.2 Financial Analysis
8.6.3 Segmental and Regional Analysis
8.6.4 Research & Development Expense
8.6.5 Recent strategies and developments:
8.6.5.1 Partnerships, Collaborations, and Agreements:
8.6.5.2 Product Launches and Product Expansions:
8.6.5.3 Acquisition and Mergers:
8.6.6 SWOT Analysis
8.7 Johnson & Johnson
8.7.1 Company Overview
8.7.2 Financial Analysis
8.7.3 Segmental & Regional Analysis
8.7.4 Research & Development Expenses
8.7.5 Recent strategies and developments:
8.7.5.1 Partnerships, Collaborations, and Agreements:
8.7.5.2 Acquisition and Mergers:
8.7.6 SWOT Analysis
8.8 Novartis AG
8.8.1 Company Overview
8.8.2 Financial Analysis
8.8.3 Segmental and Regional Analysis
8.8.4 Research & Development Expense
8.8.5 Recent strategies and developments:
8.8.5.1 Partnerships, Collaborations, and Agreements:
8.8.6 SWOT Analysis
8.9 Merck & Co., Inc.
8.9.1 Company Overview
8.9.2 Financial Analysis
8.9.3 Segmental and Regional Analysis
8.9.4 Research & Development Expenses
8.9.5 Recent strategies and developments:
8.9.5.1 Partnerships, Collaborations, and Agreements:
8.9.5.2 Acquisition and Mergers:
8.9.6 SWOT Analysis
8.10. Pfizer, Inc.
8.10.1 Company Overview
8.10.2 Financial Analysis
8.10.3 Regional & Segmental Analysis
8.10.4 Research & Development Expense
8.10.5 Recent strategies and developments:
8.10.5.1 Partnerships, Collaborations, and Agreements:
8.10.6 SWOT Analysis
Unique Offerings 